ROR1 and lymphoma: In contrast to CD19, the first clinically approved molecule for CAR T cells, which is present on the cell surface of CD19-positive lymphoma and leukemia, the orphan receptor ROR1 is expressed on many epithelial tumors and is also a target for CAR T cells32,43.